{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T08:48:40Z","timestamp":1782031720617,"version":"3.54.5"},"reference-count":53,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003321","name":"Queen's University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019711","name":"London Health Sciences Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000771","name":"Prostate Cancer UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000771","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012118","name":"Ontario Institute for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012118","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011676","name":"Elekta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011676","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ijrobp.2026.01.024","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T17:08:19Z","timestamp":1770224899000},"page":"2-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Generating the Evidence to Support Stereotactic Radiation Therapy Evolution: Challenges and a Roadmap for Progress"],"prefix":"10.1016","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3228-6042","authenticated-orcid":false,"given":"Timothy P.","family":"Hanna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Booth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina N.","family":"Sanford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Tree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue S.","family":"Yom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2026.01.024_bib0001","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1002\/cncr.34929","article-title":"Prevalence, trends, and characteristics of trials investigating local therapy in contemporary phase 3 clinical cancer research","volume":"129","author":"Sherry","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0002","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.ijrobp.2018.04.030","article-title":"Failed randomized clinical trials in radiation oncology: What can we learn?","volume":"101","author":"Nguyen","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0003","doi-asserted-by":"crossref","first-page":"4316","DOI":"10.21037\/tcr-21-1189","article-title":"Characteristics of stereotactic radiotherapy clinical trials registered on ClinicalTrials.gov","volume":"10","author":"Zhang","year":"2021","journal-title":"Transl Cancer Res"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0004","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1001\/jamaoncol.2021.0379","article-title":"Evolution of the randomized clinical trial in the era of precision oncology","volume":"7","author":"Del Paggio","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0005","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/jamaoncol.2018.0887","article-title":"Characteristics of radiotherapy trials compared with other oncological clinical trials in the past 10 years","volume":"4","author":"Liu","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0006","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1667\/RR15121.1","volume":"190","author":"Falls","year":"2018","journal-title":"Radiat Res"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0007","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/bjc.2014.448","article-title":"The lag time in initiating clinical testing of new drugs in combination with radiation therapy, a significant barrier to progress?","volume":"111","author":"Blumenfeld","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100332","article-title":"Evaluating the evidence behind the surrogate measures included in the FDA\u2019s table of surrogate endpoints as supporting approval of cancer drugs","volume":"21","author":"Gyawali","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0009","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1002\/ijc.31957","article-title":"Association between progression-free survival and patients\u2019 quality of life in cancer clinical trials","volume":"144","author":"Hwang","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0010","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djae313","article-title":"Benchmarks of success in radiotherapy vs systemic therapy: National Clinical Trials Network (NCTN) randomized controlled trials sponsored by the National Cancer Institute (NCI)","volume":"117","author":"Sanford","year":"2025","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0011","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.ijrobp.2014.11.026","article-title":"A comparison of evidence-based estimates and empirical benchmarks of the appropriate rate of use of radiation therapy in ontario","volume":"91","author":"Mackillop","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0012","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20230334","article-title":"The use of radiotherapy, surgery and chemotherapy in the curative treatment of cancer: results from the FORTY (Favourable Outcomes from RadioTherapY) project","volume":"96","author":"Mee","year":"2023","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0013","article-title":"Assessment of proton beam therapy use among patients with newly diagnosed cancer in the US, 2004-2018","volume":"5","author":"Nogueira","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0014","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ijrobp.2024.08.012","article-title":"Prostate Advanced Radiation Technologies Investigating Quality of Life (PARTIQoL): Phase III randomized clinical trial of proton therapy vs. IMRT for localized prostate cancer","volume":"120","author":"Efstathiou","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0015","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.21037\/jtd-21-1835","article-title":"Trends and costs of stereotactic body radiation therapy in metastatic non-small cell lung cancer","volume":"14","author":"Lester-Coll","year":"2022","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0016","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): A randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0017","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.1994.12.9.1796","article-title":"Fundamental dilemmas of the randomized clinical trial process: results of a survey of the 1,737 Eastern Cooperative Oncology Group investigators","volume":"12","author":"Taylor","year":"1994","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0018","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/jamaoncol.2023.2931","article-title":"From Bragg peaks to adaptive fields-the need for evidence-based adoption of new technologies in radiotherapy","volume":"9","author":"Sanford","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0019","doi-asserted-by":"crossref","first-page":"e524","DOI":"10.3747\/co.24.3662","article-title":"Identifying barriers to accrual in radiation oncology randomized trials","volume":"24","author":"Laba","year":"2017","journal-title":"Curr Oncol Tor Ont"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0020","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.ijrobp.2023.06.353","article-title":"Stereotactic ablative radiotherapy for oligo-progressive cancers: Results of the randomized phase II STOP trial","volume":"117","author":"Schellenberg","year":"2023","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0021","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1200\/JCO.23.01402","article-title":"Elucidating the benefit of radiation therapy in GI cancers: Rethinking trial end points and patient selection","volume":"42","author":"Sanford","year":"2024","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0022","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S1470-2045(09)70023-3","article-title":"Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data","volume":"10","author":"Michiels","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0023","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1177\/01945998221087712","article-title":"Quality of life in patients with recurrent and second primary head and neck cancer","volume":"168","author":"Ramprasad","year":"2023","journal-title":"Otolaryngol\u2013Head Neck Surg Off J Am Acad Otolaryngol-Head Neck Surg"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0024","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/1097-0347(200102)23:2<113::AID-HED1006>3.0.CO;2-W","article-title":"Health-related quality of life three years after diagnosis of head and neck cancer\u2013a longitudinal study","volume":"23","author":"Hammerlid","year":"2001","journal-title":"Head Neck"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0025","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1200\/JCO.24.00374","article-title":"Clinical trials\u2014real-world data to build a future for our patients","volume":"42","author":"Fahey","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110118","article-title":"Common sense (radiation) oncology: redefining targets in radiotherapy","volume":"193","author":"Sanford","year":"2024","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0027","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1200\/JOP.200028","article-title":"Challenges to National Cancer Institute-supported Cooperative Group Clinical Trial participation: An ASCO survey of cooperative group sites","volume":"6","author":"Baer","year":"2010","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0028","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.22.01826","article-title":"Population, clinical, and scientific impact of National Cancer Institute\u2019s National Clinical trials network treatment studies","volume":"41","author":"Unger","year":"2023","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0029","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.annonc.2023.05.006","article-title":"Patient-centered, self-funding dose optimization trials as a route to reduce toxicity, lower cost, and improve access to cancer therapy","volume":"34","author":"Tannock","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0030","article-title":"Coverage with evidence development program on stereotactic body radiotherapy in Belgium (2013-2019): A nationwide registry-based prospective study","volume":"44","author":"Lievens","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0031","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1177\/1740774520928426","article-title":"Practical challenges in the conduct of pragmatic trials embedded in health plans: Lessons of IMPACT-AFib, an FDA-Catalyst trial","volume":"17","author":"Garcia","year":"2020","journal-title":"Clin Trials Lond Engl"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0032","doi-asserted-by":"crossref","first-page":"e807","DOI":"10.1200\/JOP.18.00691","article-title":"Can administrative data improve the Performance of Cancer Clinical Trial economic analyses?","volume":"15","author":"Hanna","year":"2019","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0033","article-title":"Missing the target: Radiation, \u201cToxicity,\u201d and public fear","author":"Moghanaki","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0034","unstructured":"ESTRO 2026 Language Matters. [Internet]. Accessed December 6, 2025.https:\/\/www.estro.org\/Congresses\/ESTRO-2026\/ESTRO-2026-Language-matters-A-call-to-change-the-p"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003998","article-title":"Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial","volume":"19","author":"Parker","year":"2022","journal-title":"PLoS Med"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0036","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ijrobp.2021.12.173","article-title":"Local therapy outcomes and toxicity from the ATEMPT Trial (TBCRC 033): A phase II randomized trial of adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab in women with stage I HER2-positive breast cancer","volume":"113","author":"Bellon","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0037","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.ijrobp.2024.05.033","article-title":"Off-protocol radiation therapy in phase 3 metastatic solid tumor trials","volume":"120","author":"Sherry","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0038","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA8671","article-title":"PRAGMATICA-LUNG (SWOG S2302): A prospective, randomized study of ramucirumab plus pembrolizumab versus standard of care for participants previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer","volume":"43","author":"Dragnev","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0039","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12916-018-1017-7","article-title":"Adaptive designs in clinical trials: Why use them, and how to run and report them","volume":"16","author":"Pallmann","year":"2018","journal-title":"BMC Med"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0040","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.1007","article-title":"NRG-BR002: A phase IIR\/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and\/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557)","volume":"40","author":"Chmura","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0041","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.8506","article-title":"NRG-LU002: Randomized phase II\/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC)","volume":"42","author":"Iyengar","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0042","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ijrobp.2025.11.028","article-title":"Primary Endpoint Analysis of the Phase 2 DESTINATION-MRL Trial for Patients With Intermediate-Risk Prostate Cancer","volume":"125","author":"Dassen","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0043","unstructured":"ClinicalTrials.gov. Dose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions - a Randomised Trial. clinicaltrials.gov; 2025. Accessed November 26, 2025. https:\/\/clinicaltrials.gov\/study\/NCT06638541"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0044","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12874-023-01941-5","article-title":"The Trial within Cohorts (TwiCs) study design in oncology: Experience and methodological reflections","volume":"23","author":"Kessels","year":"2023","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0045","doi-asserted-by":"crossref","first-page":"S155","DOI":"10.21037\/apm.2017.06.11","article-title":"Patient preference for stereotactic radiosurgery plus or minus whole brain radiotherapy for the treatment of brain metastases","volume":"6","author":"Zeng","year":"2017","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0046","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1002\/bjs.10897","article-title":"Patients\u2019 preferences for treatment after neoadjuvant chemoradiotherapy for oesophageal cancer","volume":"105","author":"Noordman","year":"2018","journal-title":"Br J Surg"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0047","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.oraloncology.2016.09.008","article-title":"Assessing head and neck cancer patient preferences and expectations: A systematic review","volume":"62","author":"Blanchard","year":"2016","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0048","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.lungcan.2019.03.009","article-title":"Understanding patients\u2019 values and preferences regarding early stage lung cancer treatment decision making","volume":"131","author":"Sullivan","year":"2019","journal-title":"Lung Cancer Amst Neth"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0049","first-page":"3593","article-title":"Quality versus quantity in end-of-life choices of cancer patients and support persons: A discrete choice experiment","volume":"26","author":"Waller","year":"2018","journal-title":"Support Care Cancer Off J Multinatl Assoc Support Care Cancer"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0050","unstructured":"FDA. Incorporating Voluntary Patient Preference Information over the Total Product Life Cycle, September 9, 2024. Accessed December 6, 2025.https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/incorporating-voluntary-patient-preference-information-over-total-product-life-cycle"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0051","unstructured":"PREFER Consortium. PREFER Recommendations - Why, when and how to assess and use patient preferences in medical product decision-making. Version 1_1. Published online 2022. Accessed December 6, 2025.https:\/\/zenodo.org\/records\/6592304\/files\/PREFER%20Recommendations%20v1_1.pdf?download=1"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2025.111165","article-title":"Outcomes and level of evidence in radiation therapy research and different categories of radiotherapy innovations: an ESTRO-VBRO bibliometrics analysis of the literature","volume":"213","author":"Vandemaele","year":"2025","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.ijrobp.2026.01.024_bib0053","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2025.111167","article-title":"Building an appraisal framework for radiotherapy innovations in a value-based context: The ESTRO-Value-based radiation oncology categorisation system","volume":"213","author":"Vandemaele","year":"2025","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036030162600132X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036030162600132X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T08:32:01Z","timestamp":1782030721000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S036030162600132X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S036030162600132X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2026.01.024","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Generating the Evidence to Support Stereotactic Radiation Therapy Evolution: Challenges and a Roadmap for Progress","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2026.01.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}